According to the Global Cancer Observatory, ovarian cancer was the third most common cancer among women in India in 2022, ...

The European Commission has approved mirvetuximab soravtansine for select patients with pretreated folate receptor–alpha (FRα)-positive, platinum-resistant ovarian cancer.

Verastem's promising progress in RAS-driven cancers, potential FDA approval, and growth opportunities present a bullish ...

Corcept Therapeutics specializes in cortisol-modulating drugs. Click here to read why CORT stock offers investment potential.

When it comes to ovarian cancer, early detection plays a crucial role in improving survival rates. Catching the disease in ...

Mayo Clinic Comprehensive Cancer Center experts highlight breast cancer research that may reduce or eliminate the need for chemotherapy and endocrine treatments and may allow for shorter and less ...

A retrospective study found that younger patients with ER-positive, ERBB2-negative breast cancer are more prone to late ...

A key reason is the FDA’s endorsement of advancing IMNN-001 into a Phase 3 trial for advanced ovarian cancer, which demonstrates confidence in the treatment ... Moreover, previous studies, such as the ...

FDA Project Team supports the company's proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint Final Protocol submission ...

A recent trial found that Hyperthermic intraperitoneal chemotherapy (HIPEC) in addition to cytoreductive surgery has ...

The groundbreaking results of the OVATION 2 Study demonstrated a substantial 35% improvement in overall survival, equating to ...